Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration
Korean Journal of Ophthalmology · 04.11.2026
DOI: 10.3341/kjo.2026.0051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Korean Journal of Ophthalmology, online erschienen am 04.11.2026. Verfasst von Sooyeon Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
Abstract (Originalsprache)
Objectives
To evaluate the three-year long-term efficacy, treatment durability, and safety of switching to brolucizumab in patients with neovascular age-related macular degeneration (nAMD) who were refractory to previous anti-vascular endothelial growth factor (anti-VEGF) agents in a real-world setting.
Methods
This retrospective study included nAMD patients who switched to brolucizumab between July 2021 and November 2022. Clinical outcomes were evaluated based on changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and the presence of retinal fluid, as well as changes in annual injection frequency and treatment intervals. Safety outcomes, including intraocular inflammation (IOI), were also assessed.
Results
A total of 123 patients were initially reviewed. After excluding patients who did not complete the 3-year follow-up or met exclusion criteria, 47 eyes of 47 patients were included in the final efficacy analysis. Mean BCVA significantly improved from 0.33 ± 0.24 logMAR at baseline to 0.27 ± 0.20 logMAR at 3 years (p < 0.05). Mean CMT demonstrated a significant and sustained reduction from 333.36 ± 136.05 µm at baseline to 232.06 ± 68.90 µm at 3 years (p < 0.001). By the end of the 3-year period, 70.2% of patients successfully achieved an extended treatment interval of ≥16 weeks. IOI was observed in 3.3% of patients but was manageable, with no cases of retinal vasculitis or retinal vascular occlusion observed.
Conclusions
Switching to brolucizumab provided maintained visual and anatomical improvements with extended treatment intervals over 3 years. The safety profile was consistent with previous reports, and IOI events were manageable in a real-world setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
- Department of Ophthalmology, Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. ckseek@schmc.ac.kr.
Zitieren
APA
Lee, S., Sun, H. J., Lee, S. J., & Choi, K. S. (2026). Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration. Korean Journal of Ophthalmology. https://doi.org/10.3341/kjo.2026.0051
Vancouver
Lee S, Sun HJ, Lee SJ, Choi KS. Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration. Korean Journal of Ophthalmology. 2026. doi:10.3341/kjo.2026.0051
BibTeX
@article{Lee2026,
author = {Lee, Sooyeon and Sun, Hae Jung and Lee, Sung Jin and Choi, Kyung Seek},
title = {Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration},
journal = {Korean Journal of Ophthalmology},
year = {2026},
doi = {10.3341/kjo.2026.0051}
}
EUVIMED